

CITATION REPORT

List of articles citing

Clinical pharmacology of sodium butyrate in patients with acute leukemia

DOI: 10.1016/0277-5379(87)90109-x
European Journal of Cancer & Clinical Oncology, 1987,
23, 1283-7.

Source: <https://exaly.com/paper-pdf/19177042/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|-----|--|-----|-----------|
| 194 | In vitro phenotypic alteration of human melanoma cells induced by differentiating agents: heterogeneous effects on cellular growth and morphology, enzymatic activity, and antigenic expression. 1990 , 3, 223-32 | | 30 |
| 193 | Novobiocin modulates cytokeratin assembly and differentiation of human hepatoma cells induced by butyrate and teleocidin. 1991 , 60, 51-7 | | 2 |
| 192 | Induction of morphological differentiation in the human leukemic cell line K562 by exposure to thalidomide metabolites. <i>Leukemia Research</i> , 1991 , 15, 129-36 | 2.7 | 25 |
| 191 | New stable butyrate derivatives alter proliferation and differentiation in human mammary cells. <i>International Journal of Cancer</i> , 1991 , 48, 443-9 | 7.5 | 41 |
| 190 | Derivatives of butyric acid as potential anti-neoplastic agents. <i>International Journal of Cancer</i> , 1991 , 49, 66-72 | 7.5 | 87 |
| 189 | Butyric monosaccharide ester-induced cell differentiation and anti-tumor activity in mice. Importance of their prolonged biological effect for clinical applications in cancer therapy. <i>International Journal of Cancer</i> , 1991 , 49, 89-95 | 7.5 | 35 |
| 188 | The effect of sodium butyrate on the growth characteristics of human cervix tumour cells. 1992 , 65, 803-8 | | 11 |
| 187 | Action of exogenous differentiating agents on gene expression in cancer cells. 1992 , 13, 189-214 | | 6 |
| 186 | Glucosylation of butyric acid by cell suspension culture of <i>Nicotiana plumbaginifolia</i> . 1992 , 31, 1581-1583 | | 42 |
| 185 | Enhancement by stable butyrate derivatives of antitumor and antiviral actions of interferon. <i>International Journal of Cancer</i> , 1992 , 51, 596-601 | 7.5 | 18 |
| 184 | Pharmacokinetic studies of N-butyric acid mono- and polyesters derived from monosaccharides. 1992 , 81, 241-4 | | 24 |
| 183 | Butyrate-induced reactivation of the fetal globin genes: a molecular treatment for the beta-hemoglobinopathies. 1993 , 49, 133-7 | | 29 |
| 182 | Rapid alteration of c-myc and c-jun expression in leukemic cells induced to differentiate by a butyric acid prodrug. 1993 , 328, 225-9 | | 45 |
| 181 | A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. 1993 , 328, 81-6 | | 397 |
| 180 | Differentiation Therapy Is Potentiated by Chemotherapy and Hyperthermia in Human and Canine Brain Tumor Cells In Vitro. <i>Neurosurgery</i> , 1994 , 34, 657-664 | 3.2 | 15 |
| 179 | Comparison between the effect of butyric acid and its prodrug pivaloyloxymethylbutyrate on histones hyperacetylation in an HL-60 leukemic cell line. <i>International Journal of Cancer</i> , 1994 , 56, 906-9 | 7.5 | 46 |
| 178 | Isobutyramide, an orally bioavailable butyrate analogue, stimulates fetal globin gene expression in vitro and in vivo. 1994 , 88, 555-61 | | 48 |

| | | | |
|-----|---|-----|-----|
| 177 | Selection of a highly tumorigenic breast cancer cell line sensitive to estradiol to evidence in vivo the tumor-inhibitory effect of butyrate derivative Monobut-3. 1994 , 55, 951-9 | | 5 |
| 176 | Butyrate as a differentiating agent: pharmacokinetics, analogues and current status. 1994 , 78, 1-5 | | 111 |
| 175 | Reciprocal regulation of alpha-fetoprotein and albumin gene expression by butyrate in human hepatoma cells. 1994 , 107, 499-504 | | 50 |
| 174 | Glial Differentiation. <i>Neurosurgery</i> , 1995 , 36, 1-22 | 3.2 | 4 |
| 173 | Glial differentiation: a review with implications for new directions in neuro-oncology. <i>Neurosurgery</i> , 1995 , 36, 1-21; discussion 21-2 | 3.2 | 46 |
| 172 | Butyrate and phenylacetate as differentiating agents: practical problems and opportunities. 1995 , 22, 247-53 | | 70 |
| 171 | Topical treatment of refractory distal ulcerative colitis with 5-ASA and sodium butyrate. 1995 , 40, 305-7 | | 62 |
| 170 | Sodium butyrate inhibits platelet-derived growth factor-induced proliferation of vascular smooth muscle cells. 1995 , 15, 2273-83 | | 20 |
| 169 | Transcriptional upregulation of gamma-globin by phenylbutyrate and analogous aromatic fatty acids. <i>Biochemical Pharmacology</i> , 1996 , 52, 1227-33 | 6 | 15 |
| 168 | Butyrate inhibits seeding and growth of colorectal metastases to the liver in mice. 1996 , 120, 440-7; discussion 447-8 | | 34 |
| 167 | Pharmacokinetics of arginine butyrate in patients with hemoglobinopathy. 1996 , 2, 403-5 | | |
| 166 | Pharmacokinetics and safety of single oral doses of VX-366 (isobutyramide) in healthy volunteers. 1996 , 36, 617-22 | | 6 |
| 165 | Regulation of human colonic cell line proliferation and phenotype by sodium butyrate. 1996 , 41, 1989-93 | | 52 |
| 164 | Sodium butyrate delays neutrophil apoptosis: role of protein biosynthesis in neutrophil survival. 1996 , 92, 169-75 | | 49 |
| 163 | CowsTmilk fat components as potential anticarcinogenic agents. 1997 , 127, 1055-60 | | 291 |
| 162 | Overexpression of adenovirus-encoded transgenes from the cytomegalovirus immediate early promoter in irradiated tumor cells. 1997 , 8, 2117-24 | | 35 |
| 161 | Apoptotic death in adenocarcinoma cell lines induced by butyrate and other histone deacetylase inhibitors. <i>Biochemical Pharmacology</i> , 1997 , 53, 1357-68 | 6 | 139 |
| 160 | Inhibition of platelet-derived growth factor BB-induced expression of glyceraldehyde-3-phosphate dehydrogenase by sodium butyrate in rat vascular smooth muscle cells. 1997 , 17, 3420-7 | | 17 |

| | | | |
|-----|--|-----|-----|
| 159 | An anti-cancer derivative of butyric acid (pivalyloxmethyl buterate) and daunorubicin cooperatively prolong survival of mice inoculated with monocytic leukaemia cells. 1997 , 75, 850-4 | | 32 |
| 158 | Effect of sodium butyrate on human breast cancer cell lines. 1997 , 30, 149-159 | | 37 |
| 157 | Amplification of recombinant adenoviral transgene products occurs by inhibition of histone deacetylase. 1997 , 231, 201-9 | | 57 |
| 156 | Molecular Events as Targets of Anticancer Drug Therapy. 1997 , 3, 147-158 | | 2 |
| 155 | Effect of the cytostatic butyric acid pro-drug, pivaloyloxymethyl butyrate, on the tumorigenicity of cancer cells. 1997 , 123, 267-71 | | 17 |
| 154 | Butyric acid and pivaloyloxymethyl butyrate, AN-9, a novel butyric acid derivative, induce apoptosis in HL-60 cells. 1997 , 123, 152-60 | | 34 |
| 153 | Systemic short-chain fatty acids rapidly alter gastrointestinal structure, function, and expression of early response genes. 1998 , 43, 1526-36 | | 107 |
| 152 | Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units. 1998 , 16, 113-9 | | 19 |
| 151 | Indoor Air Guideline Levels for Formic, Acetic, Propionic and Butyric Acid. 1998 , 8, 8-24 | | 11 |
| 150 | Butyrate-stable monosaccharide derivatives induce maturation and apoptosis in human acute myeloid leukaemia cells. 1998 , 101, 529-38 | | 20 |
| 149 | Role of butyric acid and its derivatives in the treatment of colorectal cancer and hemoglobinopathies. 1998 , 63, 1739-60 | | 75 |
| 148 | Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma. <i>Blood Cells, Molecules, and Diseases</i> , 1998 , 24, 114-23 | 2.1 | 73 |
| 147 | Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts. 1999 , 13, 1991-2001 | | 107 |
| 146 | A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. 1999 , 96, 4592-7 | | 635 |
| 145 | Butyric acid: a role in cancer prevention. 1999 , 24, 203-209 | | 20 |
| 144 | Regioselective synthesis and biological profiling of butyric and phenylalkylcarboxylic esters derived from D-mannose and xylitol: influence of alkyl chain length on acute toxicity. 1999 , 7, 93-106 | | 22 |
| 143 | Hyaluronic acid as drug delivery for sodium butyrate: improvement of the anti-proliferative activity on a breast-cancer cell line. <i>International Journal of Cancer</i> , 1999 , 81, 411-6 | 7.5 | 87 |
| 142 | Stable prodrugs of n-butyric acid: suppression of T cell alloresponses in vitro and prolongation of heart allograft survival in a fully allogeneic rat strain combination. 1999 , 7, 221-7 | | 18 |

| | | | |
|-----|---|-----|-----|
| 141 | Effects of sodium butyrate on growth, differentiation, and apoptosis in head and neck squamous carcinoma cell lines. 2000 , 22, 247-56 | | 10 |
| 140 | Tributylin plus all-trans-retinoic acid efficiently induces fetal hemoglobin expression in human erythroleukemia cells. 2000 , 64, 319-21 | | 14 |
| 139 | Tributylin induces differentiation, growth arrest and apoptosis in androgen-sensitive and androgen-resistant human prostate cancer cell lines. <i>International Journal of Cancer</i> , 2000 , 88, 245-251 | 7.5 | 48 |
| 138 | Prodrugs of butyric acid from bench to bedside: Synthetic design, mechanisms of action, and clinical applications. <i>Drug Development Research</i> , 2000 , 50, 379-391 | 5.1 | 62 |
| 137 | Butyrate inhibits proliferation-induced proliferating cell nuclear antigen expression (PCNA) in rat vascular smooth muscle cells. 2000 , 205, 149-61 | | 39 |
| 136 | In vitro effects of cholesteryl butyrate solid lipid nanospheres as a butyric acid pro-drug on melanoma cells: evaluation of antiproliferative activity and apoptosis induction. 2000 , 18, 663-73 | | 15 |
| 135 | Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways. <i>Blood</i> , 2000 , 95, 2391-2396 | 2.2 | 183 |
| 134 | Novel mutual prodrug of retinoic and butyric acids with enhanced anticancer activity. 2000 , 43, 2962-6 | | 38 |
| 133 | Ontogeny of intestinal nutrient transport. 2000 , 78, 513-527 | | 5 |
| 132 | Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. 2000 , 9, 2923-34 | | 80 |
| 131 | Tumor cell differentiation by butyrate and environmental stress. 2001 , 171, 173-82 | | 20 |
| 130 | Therapeutic effects of sodium butyrate on glioma cells in vitro and in the rat C6 glioma model. <i>Neurosurgery</i> , 2001 , 48, 616-24; discussion 624-5 | 3.2 | 31 |
| 129 | Epstein-Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate. 2001 , 3, 177-85 | | 56 |
| 128 | Modulation of cell cycle-related protein expression by sodium butyrate in human non-small cell lung cancer cell lines. <i>International Journal of Cancer</i> , 2001 , 91, 654-7 | 7.5 | 37 |
| 127 | Significant augmentation of pro-apoptotic gene therapy by pharmacologic bcl-xl down-regulation in mesothelioma. 2001 , 8, 547-54 | | 36 |
| 126 | Downregulation of MLL-CBP fusion gene expression is associated with differentiation of SN-1 cells with t(11;16)(q23;p13). <i>Oncogene</i> , 2001 , 20, 375-84 | 9.2 | 14 |
| 125 | Differentiation therapy of human cancer: basic science and clinical applications. 2001 , 90, 105-56 | | 232 |
| 124 | Doxorubicin and a butyric acid derivative effectively reduce levels of BCL-2 protein in the cells of chronic lymphocytic leukemia patient. <i>European Journal of Haematology</i> , 2001 , 66, 263-71 | 3.8 | 10 |

| | | | |
|-----|--|-----|-----|
| 123 | Searching for the magic bullet against cancer: the butyrate saga. 2001 , 42, 275-89 | | 26 |
| 122 | Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. <i>Blood</i> , 2002 , 100, 4640-8 | 2.2 | 78 |
| 121 | The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a tumor necrosis factor-alpha-mediated process. 2002 , 277, 31-47 | | 49 |
| 120 | Sodium butyrate induces P53-independent, Fas-mediated apoptosis in MCF-7 human breast cancer cells. 2002 , 135, 79-86 | | 66 |
| 119 | Specific cell-signal targets for cancer chemotherapy. 2002 , 25, 1-10 | | 3 |
| 118 | Sodium butyrate induces alkaline phosphatase gene expression in human hepatoma cells. 1999 , 14, 156-62 | | 4 |
| 117 | Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rbeta gene. <i>Leukemia Research</i> , 2002 , 26, 1077-83 | 2.7 | 39 |
| 116 | Modified fatty acids and their possible therapeutic targets in malignant diseases. 2003 , 7, 663-77 | | 16 |
| 115 | Myelodysplastic syndrome. 2003 , 2003, 176-99 | | 37 |
| 114 | Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. 2003 , 23, 9418-27 | | 591 |
| 113 | Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. 2004 , 64, 316-21 | | 196 |
| 112 | Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. 2004 , 10, 6066-71 | | 123 |
| 111 | A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. 2004 , 10, 2289-98 | | 171 |
| 110 | Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder. 2004 , 96, 1447-57 | | 28 |
| 109 | Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. 2004 , 90, 535-41 | | 117 |
| 108 | Hyaluronic-acid butyric esters as promising antineoplastic agents in human lung carcinoma: a preclinical study. 2004 , 22, 207-17 | | 35 |
| 107 | Determination of tributyrin and its metabolite butyrate in Wistar rat plasma samples by gas chromatography/mass spectrometry. 2004 , 18, 2217-22 | | 12 |
| 106 | Sodium butyrate enhances Fas-mediated apoptosis of human hepatoma cells. 2004 , 40, 278-84 | | 37 |

| | | | |
|-----|--|-----|-----|
| 105 | Cholesteryl butyrate solid lipid nanoparticles as a butyric acid pro-drug: effects on cell proliferation, cell-cycle distribution and c-myc expression in human leukemic cells. 2004 , 15, 525-36 | | 14 |
| 104 | Hyaluronic acid butyric esters in cancer therapy. 2005 , 16, 373-9 | | 15 |
| 103 | Histone deacetylase inhibitors for treatment of hepatocellular carcinoma. 2005 , 26, 1025-33 | | 38 |
| 102 | Retinoblastoma protein is required for efficient colorectal carcinoma cell apoptosis by histone deacetylase inhibitors in the absence of p21Waf. <i>Biochemical Pharmacology</i> , 2005 , 69, 1059-67 | 6 | 14 |
| 101 | Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. <i>International Journal of Cancer</i> , 2005 , 114, 380-6 | 7.5 | 174 |
| 100 | Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. 2005 , 14, 2003-18 | | 133 |
| 99 | Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3912-22 | 2.2 | 351 |
| 98 | Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas. <i>Molecular Cancer Therapeutics</i> , 2005 , 4, 1952-61 | 6.1 | 67 |
| 97 | It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells. 2005 , 65, 6957-66 | | 57 |
| 96 | Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. 2005 , 11, 4912-22 | | 281 |
| 95 | The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters. 2005 , 48, 1042-54 | | 46 |
| 94 | Histone deacetylase inhibitors induce apoptosis with minimal viral reactivation in cells infected with Kaposi's sarcoma-associated herpesvirus. <i>Journal of Investigative Dermatology</i> , 2006 , 126, 2516-24 | 4.3 | 9 |
| 93 | Modulation of cellular radiation responses by histone deacetylase inhibitors. <i>Oncogene</i> , 2006 , 25, 3885-93 | 3.2 | 73 |
| 92 | A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamic acid, SAHA), and its metabolites in human serum. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006 , 840, 108-15 | 3.2 | 49 |
| 91 | Histone deacetylation as a target for radiosensitization. <i>Current Topics in Developmental Biology</i> , 2006 , 73, 173-204 | 5.3 | 45 |
| 90 | Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. <i>Molecular Cancer Therapeutics</i> , 2006 , 5, 1967-74 | 6.1 | 178 |
| 89 | Sodium butyrate: a chemical inducer of in vivo reactivation of herpes simplex virus type 1 in the ocular mouse model. <i>Journal of Virology</i> , 2007 , 81, 6106-10 | 6.6 | 31 |
| 88 | Inhibition of histone deacetylation: a strategy for tumor radiosensitization. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4051-6 | 2.2 | 141 |

| | | | |
|----|--|------|-----|
| 87 | A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. <i>Blood</i> , 2007 , 109, 2571-8 | 2.2 | 218 |
| 86 | Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. <i>Blood</i> , 2007 , 109, 2781-90 | 2.2 | 253 |
| 85 | Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents. <i>Blood Cells, Molecules, and Diseases</i> , 2007 , 38, 57-65 | 2.1 | 17 |
| 84 | Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. <i>Biological Psychiatry</i> , 2007 , 62, 55-64 | 7.9 | 382 |
| 83 | Optimization of short-term transgene expression by sodium butyrate and ubiquitous chromatin opening elements (UCOEs). <i>Journal of Gene Medicine</i> , 2007 , 9, 639-48 | 3.5 | 13 |
| 82 | Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line. <i>Leukemia Research</i> , 2007 , 31, 1115-23 | 2.7 | 14 |
| 81 | HLA expression in hepatocellular carcinoma cell lines. <i>Clinical and Experimental Immunology</i> , 1994 , 97, 328-33 | 6.2 | 19 |
| 80 | Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias. <i>Current Medicinal Chemistry</i> , 2008 , 15, 1274-87 | 4.3 | 35 |
| 79 | Cholesterylbutyrate solid lipid nanoparticles as a butyric acid prodrug. <i>Molecules</i> , 2008 , 13, 230-54 | 4.8 | 34 |
| 78 | The Changes of Expression of Survivin by Butyrate in HCT116 Colon Cancer Cells. <i>[Chapchi] Journal Taehan Oekwa Hakhoe</i> , 2009 , 77, 297 | | 4 |
| 77 | In vitro studies on the inhibition of colon cancer by butyrate and carnitine. <i>Nutrition</i> , 2009 , 25, 1193-201 | 4.8 | 42 |
| 76 | Retinoic acid inhibits sodium butyrate-induced monocytic differentiation of HL60 cells while synergistically inducing granulocytoid differentiation. <i>European Journal of Haematology</i> , 1991 , 46, 93-100 | 2.8 | 10 |
| 75 | Chemoprevention of rat hepatocarcinogenesis with histone deacetylase inhibitors: efficacy of tributyrin, a butyric acid prodrug. <i>International Journal of Cancer</i> , 2009 , 124, 2520-7 | 7.5 | 51 |
| 74 | Molecular targets for tumor radiosensitization. <i>Chemical Reviews</i> , 2009 , 109, 2974-88 | 68.1 | 39 |
| 73 | Chapter 11 - Solid lipid nanoparticles for brain tumors therapy: State of the art and novel challenges. <i>Progress in Brain Research</i> , 2009 , 180, 193-223 | 2.9 | 10 |
| 72 | Promise and challenges in drug discovery and development of hybrid anticancer drugs. <i>Expert Opinion on Drug Discovery</i> , 2009 , 4, 1099-111 | 6.2 | 127 |
| 71 | HPLC Assay of Phospholipase A2 Activity Using Low-Temperature Derivatization of Fatty Acids. <i>Analytical Letters</i> , 2009 , 42, 1341-1351 | 2.2 | 10 |
| 70 | Treatment strategies for spinal muscular atrophy. <i>Translational Neuroscience</i> , 2010 , 1, | 1.2 | 4 |

| | | | |
|----|--|------|-----|
| 69 | Carbon nanotubes based electrochemical biosensor for detection of formaldehyde released from a cancer cell line treated with formaldehyde-releasing anticancer prodrugs. <i>Bioelectrochemistry</i> , 2010 , 77, 94-9 | 5.6 | 41 |
| 68 | Augmentation of the anticancer effects of proteasome inhibitors by combination with sodium butyrate in human colorectal cancer cells. <i>Experimental and Therapeutic Medicine</i> , 2010 , 1, 675-693 | 2.1 | 9 |
| 67 | Sodium butyrate inhibits pathogenic yeast growth and enhances the functions of macrophages. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 2573-80 | 5.1 | 55 |
| 66 | Stable differences in intrinsic mitochondrial membrane potential of tumor cell subpopulations reflect phenotypic heterogeneity. <i>International Journal of Cell Biology</i> , 2011 , 2011, 978583 | 2.6 | 33 |
| 65 | Implications of therapy-induced selective autophagy on tumor metabolism and survival. <i>International Journal of Cell Biology</i> , 2012 , 2012, 872091 | 2.6 | 11 |
| 64 | Esters of Mono-, Di-, and Tricarboxylic Acids. 2012 , 147-352 | | 1 |
| 63 | The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. <i>Molecular Cell</i> , 2012 , 48, 612-26 | 17.6 | 491 |
| 62 | Efficacy of the dietary histone deacetylase inhibitor butyrate alone or in combination with vitamin A against proliferation of MCF-7 human breast cancer cells. <i>Brazilian Journal of Medical and Biological Research</i> , 2012 , 45, 841-50 | 2.8 | 13 |
| 61 | Chemopreventive effects of the dietary histone deacetylase inhibitor tributyrin alone or in combination with vitamin A during the promotion phase of rat hepatocarcinogenesis. <i>Journal of Nutritional Biochemistry</i> , 2012 , 23, 860-6 | 6.3 | 19 |
| 60 | Whole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs by PET. <i>Nuclear Medicine and Biology</i> , 2013 , 40, 912-8 | 2.1 | 63 |
| 59 | Epigenetic mechanisms of neurodegeneration in Huntington's disease. <i>Neurotherapeutics</i> , 2013 , 10, 664-74 | 6.6 | 65 |
| 58 | Efficient tumor targeting by anaerobic butyrate-producing bacteria. <i>Medical Hypotheses</i> , 2013 , 80, 675-83 | 3.8 | 16 |
| 57 | Butyrate increases intracellular calcium levels and enhances growth hormone release from rat anterior pituitary cells via the G-protein-coupled receptors GPR41 and 43. <i>PLoS ONE</i> , 2014 , 9, e107388 | 3.7 | 31 |
| 56 | The chemopreventive activity of the histone deacetylase inhibitor tributyrin in colon carcinogenesis involves the induction of apoptosis and reduction of DNA damage. <i>Toxicology and Applied Pharmacology</i> , 2014 , 276, 129-35 | 4.6 | 14 |
| 55 | Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review. <i>Drug Development Research</i> , 2015 , 76, 296-317 | 5.1 | 25 |
| 54 | Intraperitoneal administration of butyrate prevents the severity of acetic acid colitis in rats. <i>Journal of Zhejiang University: Science B</i> , 2015 , 16, 224-34 | 4.5 | 14 |
| 53 | The epigenetics of aging and neurodegeneration. <i>Progress in Neurobiology</i> , 2015 , 131, 21-64 | 10.9 | 247 |
| 52 | Epigenetic drugs for cancer therapy. 2015 , 397-423 | | 0 |

| | | | |
|----|---|------|-----|
| 51 | Rescue of Isolated GH Deficiency Type II (IGHD II) via Pharmacologic Modulation of GH-1 Splicing. <i>Endocrinology</i> , 2016 , 157, 3972-3982 | 4.8 | 6 |
| 50 | Effect of methyl butyrate aroma on the survival and viability of human breast cancer cells in vitro. <i>Journal of the Egyptian National Cancer Institute</i> , 2016 , 28, 81-8 | 1.9 | 5 |
| 49 | The chemopreventive activity of butyrate-containing structured lipids in experimental rat hepatocarcinogenesis. <i>Molecular Nutrition and Food Research</i> , 2016 , 60, 420-9 | 5.9 | 11 |
| 48 | Effect of butyrate enemas on gene expression profiles and endoscopic/histopathological scores of diverted colorectal mucosa: A randomized trial. <i>Digestive and Liver Disease</i> , 2016 , 48, 27-33 | 3.3 | 55 |
| 47 | Long-Term Culture of Porcine Induced Pluripotent Stem-Like Cells Under Feeder-Free Conditions in the Presence of Histone Deacetylase Inhibitors. <i>Stem Cells and Development</i> , 2016 , 25, 386-94 | 4.4 | 10 |
| 46 | Effects of supplementing a milk replacer with sodium butyrate or tributyrin on performance and metabolism of Holstein calves. <i>Animal Production Science</i> , 2016 , 56, 1834 | 1.4 | 10 |
| 45 | Spinal Muscular Atrophy. 2017 , 179-201 | | |
| 44 | Potential of Phenylbutyrate as Adjuvant Chemotherapy: An Overview of Cellular and Molecular Anticancer Mechanisms. <i>Chemical Research in Toxicology</i> , 2017 , 30, 1767-1777 | 4 | 8 |
| 43 | Conformational analysis of 9-crown-3, 9-thiacrown-3 and 9-azacrown-3. <i>Journal of Molecular Graphics and Modelling</i> , 2017 , 71, 257-267 | 2.8 | 1 |
| 42 | Systemic availability and metabolism of colonic-derived short-chain fatty acids in healthy subjects: a stable isotope study. <i>Journal of Physiology</i> , 2017 , 595, 541-555 | 3.9 | 140 |
| 41 | Targeting GH-1 splicing as a novel pharmacological strategy for growth hormone deficiency type II. <i>Biochemical Pharmacology</i> , 2017 , 124, 1-9 | 6 | 1 |
| 40 | Photoactivatable prodrugs of butyric acid based on new coumarin fused oxazole heterocycles. <i>Dyes and Pigments</i> , 2017 , 137, 91-100 | 4.6 | 9 |
| 39 | Histone Deacetylase Inhibitors and Tumor Radiosensitization. <i>Cancer Drug Discovery and Development</i> , 2017 , 57-78 | 0.3 | 1 |
| 38 | Short-Chain Fatty Acids Are Antineoplastic Agents. 2017 , | | 2 |
| 37 | Short-chain fatty acids suppress food intake by activating vagal afferent neurons. <i>Journal of Nutritional Biochemistry</i> , 2018 , 57, 130-135 | 6.3 | 76 |
| 36 | Pharmacoepigenomic Interventions as Novel Potential Treatments for Alzheimer's and Parkinson's Diseases. <i>International Journal of Molecular Sciences</i> , 2018 , 19, | 6.3 | 29 |
| 35 | Dietary tributyrin, an HDAC inhibitor, promotes muscle growth through enhanced terminal differentiation of satellite cells. <i>Physiological Reports</i> , 2018 , 6, e13706 | 2.6 | 10 |
| 34 | Lipid-regulating properties of butyric acid and 4-phenylbutyric acid: Molecular mechanisms and therapeutic applications. <i>Pharmacological Research</i> , 2019 , 144, 116-131 | 10.2 | 8 |

| | | | |
|----|---|------|----|
| 33 | Histone Deacetylase Inhibitor Tributyrin and Vitamin A in Cancer. 2019 , 1615-1636 | | 1 |
| 32 | Butyrate, a Short-Chain Fatty Acid and Histone Deacetylases Inhibitor: Nutritional, Physiological, and Pharmacological Aspects in Diabetes. 2019 , 793-807 | | 1 |
| 31 | Microbiota changes in a pediatric acute lymphocytic leukemia mouse model. <i>MicrobiologyOpen</i> , 2020 , 9, e982 | 3.4 | 5 |
| 30 | Butyrate generated by gut microbiota and its therapeutic role in metabolic syndrome. <i>Pharmacological Research</i> , 2020 , 160, 105174 | 10.2 | 23 |
| 29 | Natural Products Impacting DNA Methyltransferases and Histone Deacetylases. <i>Frontiers in Pharmacology</i> , 2020 , 11, 992 | 5.6 | 14 |
| 28 | Sodium Butyrate Selectively Kills Cancer Cells and Inhibits Migration in Colorectal Cancer by Targeting Thioredoxin-1. <i>Oncotargets and Therapy</i> , 2020 , 13, 4691-4704 | 4.4 | 14 |
| 27 | The Use of Microbial Accessible and Fermentable Carbohydrates and/or Butyrate as Supportive Treatment for Patients With Coronavirus SARS-CoV-2 Infection. <i>Frontiers in Medicine</i> , 2020 , 7, 292 | 4.9 | 10 |
| 26 | Epigenetic Modifiers and Their Inhibitors in Leukemia Treatment. 2021 , 25-66 | | |
| 25 | Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends. <i>Journal of Biomedical Science</i> , 2021 , 28, 27 | 13.3 | 25 |
| 24 | Butyrate modulates adipose-derived stem cells isolated from polygenic obese and diabetic mice to drive enhanced immunosuppression. <i>Cytotherapy</i> , 2021 , 23, 567-581 | 4.8 | 0 |
| 23 | Sodium Butyrate Protects Against Ethanol-Induced Toxicity in SH-SY5Y Cell Line. <i>Neurotoxicity Research</i> , 2021 , 39, 2186-2193 | 4.3 | 1 |
| 22 | Esters of Aromatic Mono-, Di-, and Tricarboxylic Acids, Aromatic Diacids and Di-, Tri-, Or Polyalcohols. | | 8 |
| 21 | Molecular events that regulate cell proliferation: an approach for the development of new anticancer drugs. <i>Progress in Cell Cycle Research</i> , 2000 , 4, 219-33 | | 6 |
| 20 | Butyrate. <i>Advances in Experimental Medicine and Biology</i> , 1997 , 169-181 | 3.6 | 11 |
| 19 | Targeting Histone Deacetylase as a Strategy for Cancer Prevention. 2004 , 659-678 | | 3 |
| 18 | Butyrate, a Short-Chain Fatty Acid and Histone Deacetylases Inhibitor: Nutritional, Physiological, and Pharmacological Aspects in Diabetes. 2017 , 1-15 | | 2 |
| 17 | Agents which Increase Synthesis and Release of Tissue-Type Plasminogen Activator. <i>Handbook of Experimental Pharmacology</i> , 2001 , 521-556 | 3.2 | 1 |
| 16 | Effect of the cytostatic butyric acid pro-drug, pivaloyloxymethyl butyrate, on the tumorigenicity of cancer cells. 1997 , 123, 267 | | 1 |

| | | | |
|----|---|-----|----|
| 15 | Effect of sodium butyrate on estrogen receptor and epidermal growth factor receptor gene expression in human breast cancer cell lines.. <i>Journal of Biological Chemistry</i> , 1992 , 267, 18008-18012 | 5.4 | 38 |
| 14 | Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways. <i>Blood</i> , 2000 , 95, 2391-2396 | 2.2 | 7 |
| 13 | Differentiation therapy is potentiated by chemotherapy and hyperthermia in human and canine brain tumor cells in vitro. <i>Neurosurgery</i> , 1994 , 34, 657-64 | 3.2 | 16 |
| 12 | Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms. <i>Oncotarget</i> , 2013 , 4, 622-35 | 3.3 | 34 |
| 11 | Targeting the Epigenome with Dietary Agents. <i>Oxidative Stress and Disease</i> , 2008 , | | |
| 10 | Mechanisms Involved in Enhancement of Apoptosis by Radiation or Hyperthermia in Combination with Sodium Butyrate. <i>Thermal Medicine</i> , 2010 , 26, 43-50 | 0.4 | |
| 9 | Histone Deacetylase Inhibitor Tributyrin and Vitamin A in Cancer. 2017 , 1-23 | | |
| 8 | Butyrate. <i>Prakticki i teoretski aspekti</i> , 2018 , 14, 73-76 | 0.1 | |
| 7 | Methyl Butyrate Alleviates Experimental Autoimmune Encephalomyelitis and Regulates the Balance of Effector T Cells and Regulatory T Cells. <i>Inflammation</i> , 2021 , 1 | 5.1 | 0 |
| 6 | Gut-Bone Axis: A Non-Negligible Contributor to Periodontitis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021 , 11, 752708 | 5.9 | 1 |
| 5 | Mathematical Modeling of the Gut-Bone Axis and Implications of Butyrate Treatment on Osteoimmunology.. <i>Industrial & Engineering Chemistry Research</i> , 2021 , 60, 17814-17825 | 3.9 | 1 |
| 4 | The HDAC Inhibitor Butyrate Impairs Cell Function and Activates the Disallowed Gene Hexokinase I.. <i>International Journal of Molecular Sciences</i> , 2021 , 22, | 6.3 | 0 |
| 3 | Inhibition of the HIF-1 Survival Pathway as a Strategy to Augment Photodynamic Therapy Efficacy.. <i>Methods in Molecular Biology</i> , 2022 , 2451, 285-403 | 1.4 | |
| 2 | Short-chain fatty acid-releasing nano-prodrugs for attenuating growth and metastasis of melanoma. 2023 , 159, 226-236 | | 0 |
| 1 | Self-assembling polymer-based short chain fatty acid prodrugs ameliorate non-alcoholic steatohepatitis and liver fibrosis. 2023 , 295, 122047 | | 0 |